On 23 May 2008, Sanofi Pharma Bristol-Myers Squibb officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for DuoPlavin for the prevention of atherothrombotic events.
Therapeutic Indication
### Therapeutic indication DuoPlavin is indicated for the secondary prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). DuoPlavin is a fixed-dose combination medicinal product for continuation of therapy in: - Non ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention (PCI); - ST segment elevation acute myocardial infarction (STEMI) in patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. For further information please refer to section 5.1.
Therapeutic Area (MeSH)
N/AATC Code
B01AC30
ATC Item
combinations
Pharmacotherapeutic Group
Antithrombotic agents
Active Substance (Summary)
N/AINN / Common Names
N/AEMA Name
DuoPlavin
Medicine Name
DuoPlavin
Aliases
N/ANo risk management plan link.
